Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Completed 5Terminated 4Recruiting 3Active not recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 218Breast 88Head & Neck 13Other solid neoplasm 8Tumor-Agnostic 5Other neoplasm 2NET 2Lymphoid 2Endocrine 2Thoracic 1Sarcoma 1Gynecologic 1Dermatologic 1CNS 1

Conditions

Neuroendocrine Tumors 2Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 6Everolimus 6lanreotide 5anlotinib 5Temozolomide 5Injections 4Dexmedetomidine 4Cisplatin 4surufatinib 3Thyrotropin Alfa 3Sodium Chloride 3Saline Solution 3Fluorodeoxyglucose F18 3Blood Specimen Collection 3177Lu-octreotide, DOTA(0)-Tyr(3)- 3(177)Lu-DOTA-EB-TATE 3sintilimab 2penpulimab 2cabozantinib 2Surgical Procedures, Operative 2Sorafenib 2Rosiglitazone 2Radiotherapy 2Radiofrequency Ablation 2Positron Emission Tomography Computed Tomography 2Paclitaxel 2Nivolumab 2N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 2Metformin 2Magnetic Resonance Spectroscopy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Capecitabine × Endocrine × Clear all
NCT03279601 2017-09-12

Study to Compare Capecitabine Combined With Dacarbazine(CAPDTIC) Versus Capecitabine Combined Temozolomide(CAPTEM) in Advanced and Metastatic Gastrointestinal Pancreatic and Esophageal Neuroendocrine Tumor

Peking University

Phase 2 Unknown
148 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT01203306 2010-09-16

XELBEVOCT

University of Turin, Italy

Phase 2 Unknown
42 enrolled
EndocrineNET

Carcinoma, Neuroendocrine, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡